Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9620894 | 0.94 | TSHR (0.48) | TSHRHPGDL3MBTL1CYP2A6MAOA | |
| SCHEMBL38097 | 0.86 | TSHR (0.36) | TSHRHTR2C | |
| SCHEMBL29246 | 0.72 | — | — | |
| SCHEMBL3884 | 0.68 | TSHR (0.48) | TSHRHPGDL3MBTL1CYP2A6MAOA | |
| SCHEMBL286696 | 0.68 | TSHR (0.48) | TSHRHPGDL3MBTL1CYP2A6MAOA | |
| SCHEMBL9621216 | 0.67 | TSHR (0.31) | TSHR | |
| SCHEMBL62945 | 0.67 | TSHR (0.52) | TSHRHPGDL3MBTL1CYP2A6MAOA | |
| SCHEMBL9421049 | 0.67 | TSHR (0.52) | TSHRHPGDL3MBTL1CYP2A6MAOA | |
| SCHEMBL327799 | 0.66 | TSHR (0.43) | TSHRCYP2A6MAOAMAOBHTR2C | |
| SCHEMBL8912020 | 0.66 | TSHR (0.43) | TSHRCYP2A6MAOAMAOBHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | claimed |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICAL N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| EP-1581476-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056745-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| EP-4400501-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118354995-A | Novel compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355014-A | Novel compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355010-A | Novel compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118339142-A | Novel compound and organic light emitting device using the same | 株式会社LG化学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117999260-A | Novel compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-05-07 | — | — | CN | disclosed |
| CN-117440949-A | Novel compound and organic light emitting device using the same | 株式会社LG化学 | 2024-01-23 | — | — | CN | disclosed |
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2004096807-A2 | HIV INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004056745-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| EP-0284359-B1 | 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0369810-A2 | PAF antagonists as anti-hyperendothelinemia agents | Takeda Chemical Industries, Ltd. (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | DHCR7, HSD3B2, HSD3B1 | TSHR 905/4885HPGD 54/4885L3MBTL1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.